Ex vivo expansion of cord blood and bone marrow stem cells

脐带血和骨髓干细胞的离体扩增

• 批准号: 102174
• 金额: $ 166.05万
• 依托单位: PLASTICELL LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102174
• 关键词: Ex; vivo; expansion; cord; blood

Patients with blood cancers can usually be treated by receiving a bone marrow transplant from another person. Usually this person has to be a blood relation or have a compatible tissue type to ensure the transplant is not rejected. However, finding such a match is not always simple. For some years now, women have been donating the blood found in the umblilical cord after given birth to their babies. This blood is full of stem cells which are capable of reconstituting the entire immune system of the recipient, furthermore complete matching is not required, so cord blood cells can be used to treat many more patients. Unfortunately the number of cells in each cord blood unit is limited and too small to treat most adults. We have already developed media formulations which in preliminary in vitro studies allow the blood stem/progenitor cells in the cord blood units to be expanded by at least 30-100 fold. With this project we are seeking initially to develop a clinically compliant process to expand cord blood cells ex vivo prior to transplantation so that more patients can be treated with this live saving therapy.

血癌患者通常可以通过接受另一个人的骨髓移植治疗。通常这个人必须是一个血亲或有一个兼容的组织类型，以确保移植不被拒绝。然而，找到这样的匹配并不总是那么简单。几年来，妇女们一直在捐献她们生下孩子后脐带中的血液。这种血液充满了能够重建受体整个免疫系统的干细胞，而且不需要完全匹配，因此脐带血细胞可以用于治疗更多的患者。不幸的是，每个脐带血单位中的细胞数量是有限的，而且太少，无法治疗大多数成年人。我们已经开发了培养基配方，其在初步的体外研究中允许脐带血单位中的造血干细胞/祖细胞扩增至少30-100倍。通过这个项目，我们最初寻求开发一种符合临床要求的方法，在移植前体外扩增脐带血细胞，以便更多的患者可以接受这种挽救生命的治疗。